Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
63
Language
English
Published on
31/01/25
You may also be interested by these reports :
13/08/26
Ottobock continues to deliver, with a strong set of results in 1H26. Core revenues grew by +7.7% (organic +6.7%), largely supported by a strong EMEA ...
12/08/26
Demant reported better-than-expected Q2 results, with robust top-line growth across all segments. Profitability rose by double digits in H1, and ...
12/08/26
Over the past few years, hearing aid firms have disappointed the shareholders who have supported them, resulting in a heavy price being paid. ...
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...